(S)-2-amino-N-methyl-4-(methylthio)butanamide | 68800-02-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-2-amino-N-methyl-4-(methylthio)butanamide
• 英文别名: (2S)-2-amino-N-methyl-4-(methylsulfanyl)butanamide；(2S)-2-amino-N-methyl-4-methylsulfanylbutanamide
• CAS: 68800-02-2
• 化学式: C₆H₁₄N₂OS
• mdl: MFCD14696985
• 分子量: 162.256
• InChiKey: IRZOJKYRJZTMOW-YFKPBYRVSA-N

物化性质

• 沸点：
  345.9±37.0 °C(Predicted)
• 密度：
  1.070±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  80.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (S)-2-amino-N-methyl-4-(methylthio)butanamide 在 盐酸 、 1-羟基苯并三唑 、 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 、 溶剂黄146 为溶剂， 反应 53.5h， 生成 Gln-Gln-Phe-Phe-Gly-Leu-Met-NHCH3
  参考文献：
  名称：

  Structure-activity studies on the C-terminal amide of substance P

  摘要：

  Twelve C-terminal heptapeptide analogues of substance P have been synthesized by solid phase and by the classical solution method. The modifications concerned all the C-terminal primary amide of SP and should therefore help to understand the biological significance of this carboxamide, as evaluated by in vivo and in vitro bioassays. From the results it can be seen that not the slightest change of the two amide protons is tolerated without an important loss of activity: replacement of one or two amide protons with alkyl groups, extension of the amide to the hydrazide and its alkyl analogues, and exchange of the amide with an ester or a carboxylic acid all reduce the relative activity/affinity at least by 2-fold. It is not clear for what reason all these modifications produce such a drastic activity reduction.

  DOI：

  10.1021/jm00353a009
• 作为产物：
  描述：

  N-叔丁氧羰基-L-蛋氨酸二环己胺盐 在 盐酸 作用下， 以 四氢呋喃 、 水 、 溶剂黄146 为溶剂， 反应 0.03h， 生成 (S)-2-amino-N-methyl-4-(methylthio)butanamide
  参考文献：
  名称：

  Structure-activity studies on the C-terminal amide of substance P

  摘要：

  Twelve C-terminal heptapeptide analogues of substance P have been synthesized by solid phase and by the classical solution method. The modifications concerned all the C-terminal primary amide of SP and should therefore help to understand the biological significance of this carboxamide, as evaluated by in vivo and in vitro bioassays. From the results it can be seen that not the slightest change of the two amide protons is tolerated without an important loss of activity: replacement of one or two amide protons with alkyl groups, extension of the amide to the hydrazide and its alkyl analogues, and exchange of the amide with an ester or a carboxylic acid all reduce the relative activity/affinity at least by 2-fold. It is not clear for what reason all these modifications produce such a drastic activity reduction.

  DOI：

  10.1021/jm00353a009

文献信息

• Asymmetric α-arylation of amino acids
  作者：Daniel J. Leonard、John W. Ward、Jonathan Clayden

  DOI：10.1038/s41586-018-0553-9

  日期：2018.10

  α-aryl amino acids and their derivatives are valuable precursors to bioactive molecules10,11. Here we describe the synthesis of quaternary α-aryl amino acids from enantiopure amino acid precursors by α-arylation without loss of stereochemical integrity. Our approach relies on the temporary formation of a second stereogenic centre in an N′-arylurea adduct12 of an imidazolidinone derivative6 of the precursor

  季氨基酸，其中带有氨基和羧基的 α-碳也带有两个碳取代基，作为肽构象和生物活性的修饰剂以及作为药用重要化合物的前体具有重要作用 1,2。与在该 α-碳上的对映选择性烷基化（有多种方法 3-8）相比，在 α-碳上一般对映选择性引入芳基取代基在合成上具有挑战性 9。尽管如此，由此产生的 α-芳基氨基酸及其衍生物是生物活性分子 10,11 的有价值的前体。在这里，我们描述了通过 α-芳基化从对映纯氨基酸前体合成季 α-芳基氨基酸而不损失立体化学完整性。我们的方法依赖于在前体氨基酸的咪唑啉酮衍生物 6 的 N'-芳基脲加合物中临时形成第二个立体中心，并使用容易获得的对映体纯氨基酸作为前体和不对称的来源。它避免使用有价值的过渡金属，并能够用富电子、贫电子和杂环取代基进行芳基化。产物的任一对映异构体都可由单一氨基酸前体形成。该方法实用且可扩展，并提供了生产数克数量的 α-芳基化季铵氨基酸的机会。该方法
• Asymmetric and Geometry‐Selective α‐Alkenylation of α‐Amino Acids
  作者：Hossay Abas、Josep Mas‐Roselló、Mostafa Mahmoud Amer、Derek J. Durand、Robin R. Groleau、Natalie Fey、Jonathan Clayden

  DOI：10.1002/anie.201813984

  日期：2019.2.18

  Both E‐ and Z‐N′‐alkenyl urea derivatives of imidazolidinones may be formed selectively from enantiopure α‐amino acids. Generation of their enolate derivatives in the presence of K+ and [18]crown‐6 induces intramolecular migration of the alkenyl group from N′ to Cα with retention of double bond geometry. DFT calculations indicate a partially concerted substitution mechanism. Hydrolysis of the enantiopure

  既ë -和ž - ñ咪唑啉酮类的“链烯基脲衍生物可以选择性地从对映体纯α-氨基酸形成。在存在K +和[18] crown-6的情况下生成其烯醇化物衍生物会导致烯基从N'到Cα的分子内迁移，并保留了双键的几何形状。DFT计算表明部分协调的替代机制。对映体纯产物在酸性条件下的水解揭示了具有绝对立体构型和双键几何构型的立体发散控制的季α-烯基氨基酸。
• Herstellung enantiomerenreiner<i>cis</i>- oder<i>trans</i>-konfigurierter 2-(<i>tert</i>-Butyl)-3-methylimidazolidin-4-one aus den Aminosäuren (<i>S</i>)-Alanin, (<i>S</i>)-Phenylalanin, (<i>R</i>)-Phenylglycin, (<i>S</i>)-Methionin und (<i>S</i>)-Valin
  作者：Reto Naef、Dieter Seebach

  DOI：10.1002/hlca.19850680117

  日期：1985.2.13

  Preparation of the Enantiomerically Pure cis- and trans-Configurated 2-(tert-Butyl)-3-methylimidazolidin-4-ones from the Amino Acids (S)-Alanine, (S)-Phenylalanine, (R)-Phenylglycine, (S)-Methionine, and (S)-Valine

  对映体纯的制备顺式-和反式-构型的2-（叔丁基）-3-甲基咪唑烷-4-酮从氨基酸（小号） -丙氨酸，（小号） -苯丙氨酸，（- [R ）-苯基甘氨酸，（小号）-蛋氨酸和（S）-缬氨酸
• Synthesis of 1,3-<i>cis</i>-disubstituted sterically encumbered imidazolidinone organocatalysts
  作者：Jan Wallbaum、Daniel B Werz

  DOI：10.3762/bjoc.13.254

  日期：——

  A variety of novel imidazolidinone-based organocatalysts with bulky substituents were synthesized under mild reaction conditions starting from easily accessible substrates. Different natural and unnatural amino acid methyl amides were cyclized with aromatic carbaldehydes to yield two diastereomeric MacMillan-type catalysts. Special emphasis was put on bulky residues such as mesityl and pyrene moieties.

  使用易得的底物，在温和的反应条件下合成了一系列具有庞大取代基的新型咪唑烷酮基有机催化剂。不同的天然和非天然氨基酸甲酰胺与芳香醛缩合环化，生成两种二对映异构的MacMillan型催化剂。特别强调了像二甲苯基和芘基这样的庞大取代基。
• [EN] MEXILETINE PRODRUGS<br/>[FR] PROMÉDICAMENTS DE MÉXILÉTINE
  申请人：SHIRE LLC

  公开号：WO2012085586A1

  公开（公告）日：2012-06-28

  The present invention concerns prodrugs of mexiletine (and mexiletine's active metabolite) pharmaceutical compositions containing such prodrugs. Methods for treating myotonic conditions, while reducing the inherent adverse G1 side effects associated with mexiletine, increasing the bioavailability of mexiletine, and improving the pharmacokinetic reproducibility of mexiletine with the aforementioned prodrugs are also provided.

  本发明涉及美西利汀（及美西利汀的活性代谢物）的前药，包含这些前药的药物组合物。还提供了用于治疗肌张力疾病的方法，同时减少与美西利汀相关的固有不良G1副作用，增加美西利汀的生物利用度，并通过上述前药改善美西利汀的药代动力学可重复性。